About Triptorelin
Triptorelin is a synthetic decapeptide agonist analogue of gonadotropin-releasing hormone (GnRH) used in reproductive endocrinology research. Supplied as a lyophilized powder for laboratory investigations into gonadotropin signaling and hypothalamic-pituitary-gonadal axis pathway markers. Each batch undergoes analytical verification for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: 99%+ (HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Outcomes of GnRH agonist trigger in dydrogesterone-based PPOS versus GnRH antagonist cycles: a retrospective parallel cohort in freeze-all IVF treatment.
Recent research on Triptorelin: Outcomes of GnRH agonist trigger in dydrogesterone-based PPOS versus GnRH antagonist cycles: a retrospective parallel cohort in freeze-all IVF treatment.
Read Full Study on PubMed[Efficacy of the 3-month formulation of triptoreli in children with idiopathic central precocious puberty].
Recent research on Triptorelin: [Efficacy of the 3-month formulation of triptoreli in children with idiopathic central precocious puberty].
Read Full Study on PubMedAdditional Studies
GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis.
Recent research on Triptorelin: GnRH Agonists and Antagonists in IVF/ICSI Cycles of PCOS Women: A Network Meta-Analysis.
Read on PubMedIntramuscular and subcutaneous gonadotropin-releasing hormone agonist tests for central precocious puberty in girls: a randomized controlled trial.
Recent research on Triptorelin: Intramuscular and subcutaneous gonadotropin-releasing hormone agonist tests for central precocious puberty in girls: a randomized controlled trial.
Read on PubMedPopulation Pharmacokinetics for Pediatric Extrapolation of GenSci006: A 3.75-mg Triptorelin Acetate Microsphere Formulation for Central Precocious Puberty.
Recent research on Triptorelin: Population Pharmacokinetics for Pediatric Extrapolation of GenSci006: A 3.75-mg Triptorelin Acetate Microsphere Formulation for Central Precocious Puberty.
Read on PubMedDiagnostic Usefulness of Subcutaneous Triptorelin Stimulation Testing in the Evaluation of Central Precocious Puberty in Girls.
Recent research on Triptorelin: Diagnostic Usefulness of Subcutaneous Triptorelin Stimulation Testing in the Evaluation of Central Precocious Puberty in Girls.
Read on PubMedPembrolizumab for high TMB castration-resistant prostate cancer: A precision medicine case report.
Recent research on Triptorelin: Pembrolizumab for high TMB castration-resistant prostate cancer: A precision medicine case report.
Read on PubMedEfficacy and outcomes of 6-month triptorelin formulation in girls treated for central precocious puberty for 24 months and beyond.
Recent research on Triptorelin: Efficacy and outcomes of 6-month triptorelin formulation in girls treated for central precocious puberty for 24 months and beyond.
Read on PubMedRelated Research
Purchase Triptorelin from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.